AtriCure, Inc. (NASDAQ:ATRC) Stock Has Average Price Target of $53.30 According to Brokerages

Shares of AtriCure, Inc. (NASDAQ:ATRC) have been assigned a consensus rating of “Moderate Buy” from the twelve research firms that are covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $53.30.

ATRC has been the subject of several analyst reports. BTIG Research increased their target price on AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a report on Monday, August 24th. UBS Group decreased their price target on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. Raymond James Financial set a $52.00 price objective on AtriCure in a research note on Tuesday, July 21st. Zacks Research cut shares of AtriCure from a “strong-buy” rating to a “hold” rating in a report on Monday, August 24th. Finally, Piper Sandler lifted their target price on shares of AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, August 27th.

AtriCure Price Performance

Shares of NASDAQ:ATRC opened at $58.41 on Friday. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. The stock has a market cap of $2.97 billion, a PE ratio of 278.16 and a beta of 1.26. The company’s fifty day moving average is $47.70 and its 200 day moving average is $35.70. AtriCure has a 52 week low of $25.36 and a 52 week high of $61.70.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The business had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same period in the prior year, the business posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Research analysts anticipate that AtriCure will post 0.29 earnings per share for the current year.

Insider Buying and Selling at AtriCure

In other AtriCure news, Director Maggie Yuen sold 3,500 shares of the firm’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $38.42, for a total value of $134,470.00. Following the sale, the director owned 14,015 shares of the company’s stock, valued at $538,456.30. This trade represents a 19.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Regina Groves sold 5,313 shares of the business’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $54.22, for a total transaction of $288,070.86. Following the completion of the transaction, the director owned 34,546 shares in the company, valued at $1,873,084.12. The trade was a 13.33% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 74,868 shares of company stock worth $3,317,897 over the last ninety days. 4.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ATRC. Tidal Investments LLC grew its position in shares of AtriCure by 46.2% in the 2nd quarter. Tidal Investments LLC now owns 19,091 shares of the medical device company’s stock worth $534,000 after buying an additional 6,034 shares during the last quarter. WINTON GROUP Ltd purchased a new position in shares of AtriCure during the second quarter valued at approximately $1,002,000. Engineers Gate Manager LP raised its holdings in shares of AtriCure by 12.3% during the second quarter. Engineers Gate Manager LP now owns 48,160 shares of the medical device company’s stock valued at $1,348,000 after acquiring an additional 5,283 shares in the last quarter. Integrated Wealth Concepts LLC bought a new position in shares of AtriCure during the second quarter valued at approximately $46,000. Finally, Allworth Financial LP lifted its stake in AtriCure by 372.8% in the second quarter. Allworth Financial LP now owns 1,527 shares of the medical device company’s stock worth $43,000 after acquiring an additional 1,204 shares during the period. Hedge funds and other institutional investors own 99.11% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc (NASDAQ: ATRC) is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.

Its product portfolio includes the AtriClip system for excluding the left atrial appendage, the Isolator and Synergy systems for surgical ablation, and the cryoICE system, which uses cryothermal energy in cardiac procedures.